CGD is a rare
inherited immunodeficiency syndrome, caused by the phagocytes' inability to produce (sufficient) reactive
oxygen metabolites. This dysfunction is due to a defect in the
NADPH oxidase, the
enzyme responsible for the production of
superoxide. It is composed of several subunits, two of which, gp91phox and p22phox, form the membrane-bound
cytochrome b558, while its three cytosolic components, p47phox,
p67phox and
p40phox, have to translocate to the membrane upon activation. This is a tightly and intricately controlled process that involves, among others, several low-molecular weight
GTP-binding proteins. Gp91phox is encoded on the X-chromosome and p22phox, p47phox and
p67phox on different autosomal chromosomes, and a defect in one of these components leads to CGD. This explains the variable mode of inheritance seen in this syndrome. Clinically CGD manifests itself typically already at a very young age with recurrent and serious
infections, most often caused by
catalase-positive pathogens. Modern treatment options, including prophylaxis with
trimethoprim-sulfamethoxazole and rIFN-gamma as well as early and aggressive anti-
infection therapy, have improved the prognosis of this disease dramatically. CGD, as a very well-characterized inherited affection of the hematopoietic stem cells, is predestined to be among the first diseases to profit from the advances in cutting-edge
therapeutics, such as gene therapy and in utero
stem cell transplantation.